Welch & Forbes LLC Gilead Sciences, Inc. Transaction History

Welch & Forbes LLC

$7.73 Billion
Q3 2024

A detailed history of Welch & Forbes LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Welch & Forbes LLC holds 27,180 shares of GILD stock, worth $2.52 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

27,180

Previous 27,215 0.13%

Holding current value

$2.52 Million

Previous $1.87 Million 22.01%

% of portfolio

0.03%

Previous 0.03%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 04, 2024	SELL	$66.59 - $83.99 $2,330 - $2,939	-35 Reduced 0.13%	27,180 $2.28 Million
Q2 2024 Aug 01, 2024	SELL	$63.15 - $72.88 $37,258 - $42,999	-590 Reduced 2.12%	27,215 $1.87 Million
Q1 2024 May 02, 2024	SELL	$71.58 - $87.29 $101,214 - $123,428	-1,414 Reduced 4.84%	27,805 $2.04 Million
Q4 2023 Feb 06, 2024	SELL	$73.27 - $83.09 $122,727 - $139,175	-1,675 Reduced 5.42%	29,219 $2.37 Million
Q3 2023 Nov 02, 2023	SELL	$73.94 - $80.67 $24,843 - $27,105	-336 Reduced 1.08%	30,894 $2.32 Million
Q2 2023 Jul 28, 2023	SELL	$76.01 - $86.7 $62,024 - $70,747	-816 Reduced 2.55%	31,230 $2.41 Million
Q1 2023 Apr 14, 2023	SELL	$77.31 - $88.08 $60,611 - $69,054	-784 Reduced 2.39%	32,046 $2.66 Million
Q4 2022 Feb 02, 2023	SELL	$62.32 - $89.47 $156,236 - $224,301	-2,507 Reduced 7.09%	32,830 $2.82 Million
Q3 2022 Oct 28, 2022	SELL	$59.54 - $68.01 $17,683 - $20,198	-297 Reduced 0.83%	35,337 $2.18 Million
Q2 2022 Jul 22, 2022	SELL	$57.72 - $65.01 $398,268 - $448,569	-6,900 Reduced 16.22%	35,634 $2.2 Million
Q1 2022 Apr 25, 2022	SELL	$57.92 - $72.58 $21,082 - $26,419	-364 Reduced 0.85%	42,534 $2.53 Million
Q4 2021 Jan 19, 2022	BUY	$64.88 - $73.64 $11,354 - $12,887	175 Added 0.41%	42,898 $3.11 Million
Q3 2021 Oct 13, 2021	BUY	$67.69 - $73.03 $23,759 - $25,633	351 Added 0.83%	42,723 $2.98 Million
Q2 2021 Jul 22, 2021	SELL	$63.47 - $69.35 $28,878 - $31,554	-455 Reduced 1.06%	42,372 $2.92 Million
Q1 2021 Apr 14, 2021	SELL	$60.0 - $68.46 $56,880 - $64,900	-948 Reduced 2.17%	42,827 $2.77 Million
Q4 2020 Jan 20, 2021	SELL	$56.65 - $64.55 $46,566 - $53,060	-822 Reduced 1.84%	43,775 $2.55 Million
Q3 2020 Oct 23, 2020	SELL	$62.1 - $78.08 $37,073 - $46,613	-597 Reduced 1.32%	44,597 $2.82 Million
Q2 2020 Jul 15, 2020	SELL	$72.34 - $84.0 $102,433 - $118,944	-1,416 Reduced 3.04%	45,194 $3.48 Million
Q1 2020 Apr 17, 2020	SELL	$62.63 - $80.22 $1.87 Million - $2.4 Million	-29,868 Reduced 39.05%	46,610 $3.49 Million
Q4 2019 Jan 17, 2020	SELL	$61.62 - $67.78 $1.79 Million - $1.97 Million	-29,019 Reduced 27.51%	76,478 $4.97 Million
Q3 2019 Oct 11, 2019	SELL	$62.51 - $69.0 $341,679 - $377,154	-5,466 Reduced 4.93%	105,497 $6.69 Million
Q2 2019 Jul 12, 2019	SELL	$61.87 - $69.38 $1.48 Million - $1.66 Million	-23,903 Reduced 17.72%	110,963 $7.5 Million
Q1 2019 Apr 29, 2019	SELL	$62.53 - $70.05 $568,960 - $637,384	-9,099 Reduced 6.32%	134,866 $8.77 Million
Q4 2018 Feb 05, 2019	SELL	$60.54 - $79.0 $212,192 - $276,895	-3,505 Reduced 2.38%	143,965 $9.01 Million
Q3 2018 Oct 17, 2018	SELL	$71.28 - $78.92 $19,245 - $21,308	-270 Reduced 0.18%	147,470 $11.4 Million
Q2 2018 Jul 16, 2018	SELL	$64.88 - $75.68 $514,303 - $599,915	-7,927 Reduced 5.09%	147,740 $10.5 Million
Q1 2018 Apr 12, 2018	SELL	$72.84 - $88.8 $140,508 - $171,295	-1,929 Reduced 1.22%	155,667 $11.7 Million
Q4 2017 Jan 26, 2018	SELL	$71.15 - $83.52 $198,650 - $233,187	-2,792 Reduced 1.74%	157,596 $11.3 Million
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $11.6 Million - $13.7 Million	160,388	160,388 $13 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Welch & Forbes LLC, based on Form 13F filings with the SEC.

News

Stay updated on Welch & Forbes LLC with notifications on news.

Account